Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

Abstract Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor that is highly
expressed by exhausted T cells. LAG-3 is a promising immunotherapeutic target, with more …

The strategy of combining a vaccine with immune checkpoint inhibitors has been widely
investigated in cancer management, but the complete response rate for this strategy is still …

T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

Infection susceptibility, poor vaccination efficacy, age-related disease onset, and neoplasms
are linked to innate and adaptive immune dysfunction that accompanies aging (known as …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However,
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the …

A paradigm shift in the understanding of the exhausted CD8+ T cell (Tex) lineage is
underway. Originally thought to be a uniform population that progressively loses effector …

Colorectal cancers (CRCs) arise from precursor polyps whose cellular origins, molecular
heterogeneity, and immunogenic potential may reveal diagnostic and therapeutic insights …